Skip to content

Drug interactions

Darolutamide + Efavirenz

Severity: Major

Darolutamide and Efavirenz: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Efavirenz may decrease darolutamide exposure because darolutamide is cleared by CYP3A4 and P-gp, which could reduce control of prostate cancer.

What this interaction means in plain words

Darolutamide and Efavirenz can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Darolutamide belongs to Miscellaneous; Efavirenz belongs to Anti Virals.

Evidence level: Moderate

Why it happens

Efavirenz induces CYP3A4 and P-gp, lowering darolutamide concentrations.

What to do

Avoid combined P-gp and CYP3A4 inducers where possible. If it cannot be avoided, monitor PSA and clinical response.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Darolutamide and Efavirenz, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Darolutamide with Efavirenz?

MediHelp rates the interaction as major. Darolutamide and Efavirenz can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Efavirenz may decrease darolutamide exposure because darolutamide is cleared by CYP3A4 and P-gp, which could reduce control of prostate cancer.

How serious is the interaction between Darolutamide and Efavirenz?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combined P-gp and CYP3A4 inducers where possible. If it cannot be avoided, monitor PSA and clinical response.

What other medicines interact with Efavirenz?

MediHelp also lists interactions of Efavirenz with, for example, Cobimetinib, Dienogest / estradiol valerate, Dihydroergotamine intranasal. The full list is on the Efavirenz page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in